As expected, the model predicts that temozolomide (TMZ) will have a stronger antitumor effect (lower IC50) in glioma patients with MGMT promoter methylation, which reduces expression of the DNA repair enzyme MGMT (Figure 1(BI)). This evidence concerns the gene LIG4 and central nervous system cancer.